Natural killer cells play a key role in the antitumor immunity generated by chaperone-rich cell lysate vaccination
Yi Zeng
Department of Pediatrics, Steele Children's Research Center, University of Arizona, Tucson, AZ
Search for more papers by this authorXinchun Chen
Department of Pediatrics, Steele Children's Research Center, University of Arizona, Tucson, AZ
Search for more papers by this authorNicolas Larmonier
Department of Pediatrics, Steele Children's Research Center, University of Arizona, Tucson, AZ
Search for more papers by this authorClaire Larmonier
Department of Pediatrics, Steele Children's Research Center, University of Arizona, Tucson, AZ
Search for more papers by this authorGang Li
Department of Pediatrics, Steele Children's Research Center, University of Arizona, Tucson, AZ
Search for more papers by this authorMarjan Sepassi
Department of Pediatrics, Steele Children's Research Center, University of Arizona, Tucson, AZ
Search for more papers by this authorMarilyn Marron
Department of Pediatrics, Steele Children's Research Center, University of Arizona, Tucson, AZ
Search for more papers by this authorSamita Andreansky
Department of Pediatrics, Steele Children's Research Center, University of Arizona, Tucson, AZ
Search for more papers by this authorCorresponding Author
Emmanuel Katsanis
Department of Pediatrics, Steele Children's Research Center, University of Arizona, Tucson, AZ
Fax: +520-626-6986
University of Arizona, Department of Pediatrics, 1501 N. Campbell Avenue, PO Box 245073, Tucson, AZ 85724-5073Search for more papers by this authorYi Zeng
Department of Pediatrics, Steele Children's Research Center, University of Arizona, Tucson, AZ
Search for more papers by this authorXinchun Chen
Department of Pediatrics, Steele Children's Research Center, University of Arizona, Tucson, AZ
Search for more papers by this authorNicolas Larmonier
Department of Pediatrics, Steele Children's Research Center, University of Arizona, Tucson, AZ
Search for more papers by this authorClaire Larmonier
Department of Pediatrics, Steele Children's Research Center, University of Arizona, Tucson, AZ
Search for more papers by this authorGang Li
Department of Pediatrics, Steele Children's Research Center, University of Arizona, Tucson, AZ
Search for more papers by this authorMarjan Sepassi
Department of Pediatrics, Steele Children's Research Center, University of Arizona, Tucson, AZ
Search for more papers by this authorMarilyn Marron
Department of Pediatrics, Steele Children's Research Center, University of Arizona, Tucson, AZ
Search for more papers by this authorSamita Andreansky
Department of Pediatrics, Steele Children's Research Center, University of Arizona, Tucson, AZ
Search for more papers by this authorCorresponding Author
Emmanuel Katsanis
Department of Pediatrics, Steele Children's Research Center, University of Arizona, Tucson, AZ
Fax: +520-626-6986
University of Arizona, Department of Pediatrics, 1501 N. Campbell Avenue, PO Box 245073, Tucson, AZ 85724-5073Search for more papers by this authorAbstract
Tumor derived chaperone-rich cell lysate (CRCL) when isolated from tumor tissues is a potent vaccine that contains at least 4 of the highly immunogenic heat shock proteins (HSP) such as HSP70, HSP90, glucose related protein 94 and calreticulin. We have previously documented that CRCL provides both a source of tumor antigens and danger signals triggering dendritic cell (DC) activation. Immunization with tumor derived CRCL elicits tumor-specific T cell responses leading to tumor regression. In the current study, we further dissect the mechanisms by which CRCL simulates the immune system, and demonstrate that natural killer (NK) cells are required for effective antitumor effects to take place. Our results illustrate that CRCL directly stimulates proinflammatory cytokine and chemokine production by NK cells, which may lead to activation and recruitment of macrophages at the tumor site. Thus, this report provides further insight into the function of CRCL as an immunostimulant against cancer. © 2006 Wiley-Liss, Inc.
References
- 1 Trinchieri G. Biology of natural killer cells. Adv Immunol 1989; 47: 187–376.
- 2 Bancroft GJ. The role of natural killer cells in innate resistance to infection. Curr Opin Immunol 1993; 5: 503–10.
- 3 Trinchieri G. Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev Immunol 2003; 3: 133–46.
- 4 Ellis RJ. The molecular chaperone concept. Semin Cell Biol 1990; 1: 1–9.
- 5 Young DB. Chaperonins and the immune response. Semin Cell Biol 1990; 1: 27–35.
- 6 Vabulas RM, Ahmad-Nejad P, da Costa C, Miethke T, Kirschning CJ, Hacker H, Wagner H. Endocytosed HSP60s use toll-like receptor 2 (TLR2) and TLR4 to activate the toll/interleukin-1 receptor signaling pathway in innate immune cells. J Biol Chem 2001; 276: 31332–9.
- 7 Tobian AA, Harding CV, Canaday DH. Mycobacterium tuberculosis heat shock fusion protein enhances class I MHC cross-processing and -presentation by B lymphocytes. J Immunol 2005; 174: 5209–14.
- 8 Multhoff G. Activation of natural killer cells by heat shock protein 70. Int J Hyperthermia 2002; 18: 576–85.
- 9 Krause SW, Gastpar R, Andreesen R, Gross C, Ullrich H, Thonigs G, Pfister K, Multhoff G. Treatment of colon and lung cancer patients with ex vivo heat shock protein 70-peptide-activated, autologous natural killer cells: a clinical phase i trial. Clin Cancer Res 2004; 10: 3699–707.
- 10 Zeng Y, Feng H, Graner MW, Katsanis E. Tumor-derived, chaperone-rich cell lysate activates dendritic cells and elicits potent antitumor immunity. Blood 2003; 101: 4485–91.
- 11 Graner M, Zeng Y, Feng H, Katsanis E. Tumor-derived chaperone-rich cell lysates are effective therapeutic vaccines against a variety of cancers. Cancer Immunol Immunother 2003; 52: 226–34.
- 12 Feng H, Zeng Y, Graner MW, Likhacheva A, Katsanis E. Exogenous stress proteins enhance the immunogenicity of apoptotic tumor cells and stimulate antitumor immunity. Blood 2003; 101: 245–52.
- 13 Chen X, Zeng Y, Li G, Larmonier N, Graner MW, Katsanis E. Peritransplantation vaccination with chaperone-rich cell lysate induces antileukemia immunity. Biol Blood Marrow Transplant 2006; 12: 275–83.
- 14 Chen W, Qin H, Reese VA, Cheever MA. CTLs specific for bcr-abl joining region segment peptides fail to lyse leukemia cells expressing p210 bcr-abl protein. J Immunother 1998; 21: 257–68.
- 15 Korten S, Volkmann L, Saeftel M, Fischer K, Taniguchi M, Fleischer B, Hoerauf A. Expansion of NK cells with reduction of their inhibitory Ly-49A, Ly-49C, and Ly-49G2 receptor-expressing subsets in a murine helminth infection: contribution to parasite control. J Immunol 2002; 168: 5199–206.
- 16 Micallef MJ, Yoshida K, Kawai S, Hanaya T, Kohno K, Arai S, Tanimoto T, Torigoe K, Fujii M, Ikeda M, Kurimoto M. In vivo antitumor effects of murine interferon-γ-inducing factor/interleukin-18 in mice bearing syngeneic Meth A sarcoma malignant ascites. Cancer Immunol Immunother 1997; 43: 361–7.
- 17 He L, Feng H, Raymond A, Kreeger M, Zeng Y, Graner M, Whitesell L, Katsanis E. Dendritic-cell-peptide immunization provides immunoprotection against bcr-abl-positive leukemia in mice. Cancer Immunol Immunother 2001; 50: 31–40.
- 18 Gokden M, Shinde A. Recent immunohistochemical markers in the differential diagnosis of primary and metastatic carcinomas of the liver. Diagn Cytopathol 2005; 33: 166–72.
- 19 Zeng Y, Graner MW, Feng H, Li G, Katsanis E. Imatinib mesylate effectively combines with chaperone-rich cell lysate-loaded dendritic cells to treat bcr-abl+ murine leukemia. Int J Cancer 2004; 110: 251–9.
- 20 Borg C, Terme M, Taieb J, Menard C, Flament C, Robert C, Maruyama K, Wakasugi H, Angevin E, Thielemans K, Le Cesne A, Chung-Scott V et al. Novel mode of action of c-kit tyrosine kinase inhibitors leading to NK cell-dependent antitumor effects. J Clin Invest 2004; 114: 379–88.
- 21 Zeng Y, Graner MW, Thompson S, Marron M, Katsanis E. Induction of BCR-ABL-specific immunity following vaccination with chaperone-rich cell lysates derived from BCR-ABL + tumor cells. Blood 2005; 105: 2016–22.
- 22 Tsujimoto H, Uchida T, Efron PA, Scumpia PO, Verma A, Matsumoto T, Tschoeke SK, Ungaro RF, Ono S, Seki S, Clare-Salzler MJ, Baker HV et al. Flagellin enhances NK cell proliferation and activation directly and through dendritic cell-NK cell interactions. J Leukoc Biol 2005; 78: 888–97.
- 23 Finkelman FD, Yang M, Orekhova T, Clyne E, Bernstein J, Whitekus M, Diaz-Sanchez D, Morris SC. Diesel exhaust particles suppress in vivo IFN-γ production by inhibiting cytokine effects on NK and NKT cells. J Immunol 2004; 172: 3808–13.
- 24 Dalton DK, Pitts-Meek S, Keshav S, Figari IS, Bradley A, Stewart TA. Multiple defects of immune cell function in mice with disrupted interferon-γ genes. Science 1993; 259: 1739–42.
- 25 Lee CK, Rao DT, Gertner R, Gimeno R, Frey AB, Levy DE. Distinct requirements for IFNs and STAT1 in NK cell function. J Immunol 2000; 165: 3571–7.
- 26 Vigorito E, Gambardella L, Colucci F, McAdam S, Turner M. Vav proteins regulate peripheral B-cell survival. Blood 2005; 106: 2391–8.
- 27 Sica A, Dorman L, Viggiano V, Cippitelli M, Ghosh P, Rice N, Young HA. Interaction of NF-κB and NFAT with the interferon-γ promoter. J Biol Chem 1997; 272: 30412–20.
- 28 Robinson D, Shibuya K, Mui A, Zonin F, Murphy E, Sana T, Hartley SB, Menon S, Kastelein R, Bazan F, O'Garra A. IGIF does not drive Th1 development but synergizes with IL-12 for interferon-γ production and activates IRAK and NFκB. Immunity 1997; 7: 571–81.
- 29 Matsumoto H, Suzuki K, Tsuyuguchi K, Tanaka E, Amitani R, Maeda A, Yamamoto K, Sasada M, Kuze F. Interleukin-12 gene expression in human monocyte-derived macrophages stimulated with Mycobacterium bovis BCG: cytokine regulation and effect of NK cells. Infect Immun 1997; 65: 4405–10.
- 30 Kanakaraj P, Ngo K, Wu Y, Angulo A, Ghazal P, Harris CA, Siekierka JJ, Peterson PA, Fung-Leung WP. Defective interleukin (IL)-18-mediated natural killer and T helper cell type 1 responses in IL-1 receptor-associated kinase (IRAK)-deficient mice. J Exp Med 1999; 189: 1129–38.
- 31 Dorner BG, Scheffold A, Rolph MS, Huser MB, Kaufmann SH, Radbruch A, Flesch IE, Kroczek RA. MIP-1α, MIP-1β, RANTES, and ATAC/lymphotactin function together with IFN-γ as type 1 cytokines. Proc Natl Acad Sci USA 2002; 99: 6181–6.
- 32 Piccioli D, Sbrana S, Melandri E, Valiante NM. Contact-dependent stimulation and inhibition of dendritic cells by natural killer cells. J Exp Med 2002; 195: 335–41.
- 33 Tracey KJ, Cerami A. Tumor necrosis factor: a pleiotropic cytokine and therapeutic target. Annu Rev Med 1994; 45: 491–503.
- 34 Pisegna S, Pirozzi G, Piccoli M, Frati L, Santoni A, Palmieri G. p38 MAPK activation controls the TLR3-mediated up-regulation of cytotoxicity and cytokine production in human NK cells. Blood 2004; 104: 4157–64.
- 35 Hart OM, Athie-Morales V, O'Connor GM, Gardiner CM. TLR7/8-mediated activation of human NK cells results in accessory cell-dependent IFN-{γ} production. J Immunol 2005; 175: 1636–42.
- 36 Boehm U, Klamp T, Groot M, Howard JC. Cellular responses to interferon-γ. Annu Rev Immunol 1997; 15: 749–95.
- 37 Young HA, Hardy KJ. Role of interferon-γ in immune cell regulation. J Leukoc Biol 1995; 58: 373–81.
- 38 Cao MY, Lee Y, Feng N, Li H, Du C, Miao D, Li J, Lee V, Jin H, Wang M, Gu X, Wright JA et al. NK cell activation and tumor infiltration are involved in the antitumor mechanism of Virulizin. Cancer Immunol Immunother 2005; 54: 229–42.
- 39 Massa C, Melani C, Colombo MP. Chaperon and adjuvant activity of hsp70: different natural killer requirement for cross-priming of chaperoned and bystander antigens. Cancer Res 2005; 65: 7942–9.
- 40 Schindler C, Darnell JE,Jr. Transcriptional responses to polypeptide ligands: the JAK-STAT pathway. Annu Rev Biochem 1995; 64: 621–51.
- 41 Meraz MA, White JM, Sheehan KC, Bach EA, Rodig SJ, Dighe AS, Kaplan DH, Riley JK, Greenlund AC, Campbell D, Carver-Moore K, DuBois RN et al. Targeted disruption of the Stat1 gene in mice reveals unexpected physiologic specificity in the JAK-STAT signaling pathway. Cell 1996; 84: 431–42.
- 42 Li Y, Zhang T, Ho C, Orange JS, Douglas SD, Ho WZ. Natural killer cells inhibit hepatitis C virus expression. J Leukoc Biol 2004; 76: 1171–9.
- 43 Zhou J, Zhang J, Lichtenheld MG, Meadows GG. A role for NF-κ B activation in perforin expression of NK cells upon IL-2 receptor signaling. J Immunol 2002; 169: 1319–25.
- 44 Guidotti LG, Chisari FV. Noncytolytic control of viral infections by the innate and adaptive immune response. Annu Rev Immunol 2001; 19: 65–91.
- 45 Moser B, Loetscher P. Lymphocyte traffic control by chemokines. Nat Immunol 2001; 2: 123–8.
- 46 Murphy PM, Baggiolini M, Charo IF, Hebert CA, Horuk R, Matsushima K, Miller LH, Oppenheim JJ, Power CA. International union of pharmacology. XXII. Nomenclature for chemokine receptors. Pharmacol Rev 2000; 52: 145–76.
- 47 Uguccioni M, D'Apuzzo M, Loetscher M, Dewald B, Baggiolini M. Actions of the chemotactic cytokines MCP-1, MCP-2, MCP-3, RANTES, MIP-1 α and MIP-1 β on human monocytes. Eur J Immunol 1995; 25: 64–8.
- 48 Taub DD, Conlon K, Lloyd AR, Oppenheim JJ, Kelvin DJ. Preferential migration of activated CD4 + and CD8 + T cells in response to MIP-1 α and MIP-1 β. Science 1993; 260: 355–8.
- 49 Chalifour A, Jeannin P, Gauchat JF, Blaecke A, Malissard M, N′Guyen T, Thieblemont N, Delneste Y. Direct bacterial protein PAMP recognition by human NK cells involves TLRs and triggers γ-defensin production. Blood 2004; 104: 1778–83.
- 50 Ferlazzo G. Natural killer and dendritic cell liaison: recent insights and open questions. Immunol Lett 2005; 101: 12–17.
- 51 Munz C, Dao T, Ferlazzo G, de Cos MA, Goodman K, Young JW. Mature myeloid dendritic cell subsets have distinct roles for activation and viability of circulating human natural killer cells. Blood 2005; 105: 266–73.
- 52 Aliberti J, Reis e Sousa C, Schito M, Hieny S, Wells T, Huffnagle GB, Sher A. CCR5 provides a signal for microbial induced production of IL-12 by CD8 α + dendritic cells. Nat Immunol 2000; 1: 83–7.
- 53 Martin-Fontecha A, Thomsen LL, Brett S, Gerard C, Lipp M, Lanzavecchia A, Sallusto F. Induced recruitment of NK cells to lymph nodes provides IFN-γ for T(H)1 priming. Nat Immunol 2004; 5: 1260–5.
- 54 Mosmann TR, Sad S. The expanding universe of T-cell subsets: Th1, Th2 and more. Immunol Today 1996; 17: 138–46.
Citing Literature
